Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1852 results
August 2018
-
Story Discovery
Teaming up with academia to discover medicines
The Novartis Faculty of Scholars initiative connects academic researchers with deep knowledge and big ideas to scientists in its drug discovery labs.
-
Press release
Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)
The EC approval is based on the first global CAR-T registration trials, which included patients from eight European countries and demonstrated durable responses and a consistent safety profile in… -
Press release
Novartis erhält die Zulassung für seine CAR-T-Zell-Therapie Kymriah® (Tisagenlecleucel) von der Europäischen Kommission
Die Zulassung durch die EK basiert auf den ersten globalen CAR-T-Zulassungsstudien, an denen Patienten aus acht europäischen Ländern teilnahmen und die ein dauerhaftes Ansprechen und ein… -
Press release
Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode
TRANSITION shows that Entresto can be safely initiated shortly after an acute heart failure episode, both in the hospital and in an out-patient setting and in a wide range of stabilized patients[1… -
Ad hoc release
SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation
SOLAR-1 evaluated BYL719 plus fulvestrant vs. fulvestrant alone in HR+/HER2- advanced breast cancer patients with PIK3CA mutations who progressed on or following treatment with an aromatase… -
Story From Our Labs
Neuroscientists target Alzheimer’s “silent stage”
Research exploring the first visible changes in the brain is helping scientists evaluate new potential treatments for Alzheimer’s.
-
Ad hoc release
Novartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer
Basel, August 14, 2018 - Novartis announced today the appointment of Dr Klaus Moosmayer as Chief Ethics, Risk and Compliance Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and… -
Ad hoc release
Novartis ernennt Dr. Klaus Moosmayer zum Chief Ethics, Risk and Compliance Officer
Basel, 14. August 2018 - Novartis hat heute die Ernennung von Dr. Klaus Moosmayer zum Chief Ethics, Risk and Compliance Officer bekanntgegeben. Er wird an Vas Narasimhan, M.D., den CEO von… -
Story Discovery
New drug manufacturing tools change pharma chemistry
The modernization and miniaturization of pharmaceutical production could expand the range of ingredients medicinal chemists use to make new drugs.
-
Story Discovery
Embracing big data to understand complex diseases
Researchers discover that networks of proteins circulating in the blood influence the development and progression of chronic diseases.
-
Story Discovery
Discovery gives cystic fibrosis researchers new direction
Novartis-Harvard team identifies a new type of cell that is key to the disease.
